Vol 4, No 2 (2018)
Review paper
Published online: 2018-06-20
Paraneoplastic syndromes in rheumatology
Forum Reumatol 2018;4(2):108-112.
Abstract
Zespoły paranowotworowe są to objawy lub zespoły objawów towarzyszące chorobie nowotworowej, które często ustępują po skutecznym wyleczeniu nowotworu. Przyczyny zespołów paranowotworowych nie zostały w pełni poznane. Mechanizmy związane są z nieprawidłowym wydzielania hormonów lub cytokin, a także z wytwarzaniem przeciwciał skierowanych przeciw nowotworowi. Najczęstsze zespoły paranowotworowe objawiają się pod postacią zespołów neurologicznych, zaburzeń hematologicznych, zmian skórnych. Artykuł przedstawia związek nowotworów złośliwych z autoimmunologicznymi chorobami tkanki łącznej.
Forum Reumatol. 2018, tom 4, nr 2: 108–112
Keywords: zespoły paranowotworowenowotwory złośliwechoroby tkanki łącznej
References
- Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860–867.
- Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008; 454(7203): 436–444.
- Bojinca V, Janta I. Rheumatic Diseases and Malignancies. Journal of Clinical Medicine. 2012(7): 364–371.
- Szekanecz E, András C, Sándor Z, et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev. 2006; 6(1): 42–47.
- Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349(16): 1526–1533.
- Tomkiel JE, Alansari H, Tang N, et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res. 2002; 8(3): 752–758.
- Frenkel K, Karkoszka J, Glassman T, et al. Systemic biomarkers of cancer risk. Cancer Detect Prev. 1996; 20: 234.
- Frenkel K, Karkoszka J, Glassman T, et al. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev. 1998; 7(1): 49–57.
- Burnham TK. Antinuclear antibodies in patients with malignancies. Lancet. 1972; 2(7774): 436.
- Wasserman J, Glas U, Blomgren H. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin Exp Immunol. 1975; 19(3): 417–422.
- Imai H, Ochs RL, Kiyosawa K, et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992; 140(4): 859–870.
- Zuber M. Positive antinuclear antibodies in malignancies. Ann Rheum Dis. 1992; 51(4): 573–574.
- Solans-Laqué R, Pérez-Bocanegra C, Salud-Salvia A, et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus. 2004; 13(3): 159–164.
- Bei R, Masuelli L, Palumbo C, et al. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett. 2009; 281(1): 8–23.
- Whitehouse JM, Holborow EJ. Smooth muscle antibody in malignant disease. Br Med J. 1971; 4(5786): 511–513.
- Shield F, Shiel WC, Jason M, et al. The diagnostic associations of patients with antinuclear antibodies reffered to a community theumatologist. J Rheumatol. 1989; 16: 782–5.
- Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. British Journal of Cancer. 1995; 72(2): 447–451.
- Lossos IS, Bogomolski-Yahalom V, Matzner Y. Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol. 1998; 57(2): 139–143.
- Fromentel CDe, Chandrasekaran K, May P, et al. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. International Journal of Cancer. 1987; 39(2): 185–189.
- Yamauchi T, Naoe T, Kurosawa Y, et al. Autoantibodies to c-myc nuclear protein products in autoimmune disease. Immunology. 1990; 69(1): 117–120.
- Doyle GA, Bourdeau-Heller JM, Coulthard S, et al. Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein. Cancer Res. 2000; 60(11): 2756–2759.
- Ben-Mahrez K, Sorokine I, Thierry D, et al. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer. 1990; 46(1): 35–38.
- Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357(9250): 96–100.
- Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, et al. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore). 1998; 77(6): 403–418.
- Zehnder P, Jenni W, Aeschlimann AG. Systemic vasculitis and solid tumors (epitheliomas). Rev Rhum Engl Ed. 1998; 65(6): 442.
- Apor E, O'Brien J, Stephen M, et al. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014; 38(9): 1067–1071.
- Goobie GC, Bernatsky S, Ramsey-Goldman R, et al. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol. 2015; 27(5): 454–460.
- Swierkot J, Lewandowicz-Uszyńska A, Bogunia-Kubik K. Paraneoplastic syndromes and rheumatic diseases. Postepy Hig Med Dosw (Online). 2014; 68: 944–954.
- Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010; 62(9): 2787–2795.
- Onishi A, Sugiyama D, Kumagai S, et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013; 65(7): 1913–1921.
- Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981; 95(3): 288–292.
- Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992; 19(2): 294–296.
- Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2012; 91(1): 1–9.
